Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia.

about

Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia.

Item

http://www.wikidata.org/entity/Q51615048

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Changes from imatinib mesylate ...... chronic myelogenous leukemia.

@en

Changes from imatinib mesylate ...... chronic myelogenous leukemia.

@nl

type

Item

label

Changes from imatinib mesylate ...... chronic myelogenous leukemia.

@en

Changes from imatinib mesylate ...... chronic myelogenous leukemia.

@nl

prefLabel

Changes from imatinib mesylate ...... chronic myelogenous leukemia.

@en

Changes from imatinib mesylate ...... chronic myelogenous leukemia.

@nl

P1476

Changes from imatinib mesylate ...... chronic myelogenous leukemia.

@en

P2093

Akihisa Hino

http://www.w3.org/2001/XMLSchema#string

Hiroaki Masaie

http://www.w3.org/2001/XMLSchema#string

Hitoshi Yoshida

http://www.w3.org/2001/XMLSchema#string

Jun Ishikawa

http://www.w3.org/2001/XMLSchema#string

Midori Koike

http://www.w3.org/2001/XMLSchema#string

Ryota Minami

http://www.w3.org/2001/XMLSchema#string

Yuma Tada

http://www.w3.org/2001/XMLSchema#string

P2860

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study.

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins

P2888

s12185-016-2071-6

P304

605-611

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12185-016-2071-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27460678

http://www.w3.org/2001/XMLSchema#string